Trial Profile
Additive effect of zoledronic acid on hormone-sensitive prostate cancer patients with bone metastasis treated by hormonal therapy: a prospective, multicenter study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 May 2018
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Biomarker; Therapeutic Use
- 24 May 2018 Status changed from recruiting to completed.
- 27 May 2013 New trial record